Treatment of Atypical Pneumonia

First-Line Treatment Options

The American Thoracic Society recommends doxycycline 100 mg IV/PO twice daily for 7-14 days as the preferred first-line agent for Mycoplasma pneumoniae and other atypical pathogens due to its efficacy and relatively lower GI side effect profile 1, 2
Azithromycin is an alternative first-line option with dosing of 500 mg PO on day 1, then 250 mg PO daily for 4 days, but has a higher incidence of GI effects 1, 2

For Mycoplasma pneumoniae, the preferred treatment is doxycycline 100 mg IV/PO twice daily for 7-14 days, with an alternative option of azithromycin, levofloxacin, or moxifloxacin 1
For Chlamydophila pneumoniae, the preferred treatment is azithromycin 500 mg PO on day 1, then 250 mg PO daily for 4 days, with an alternative option of doxycycline, clarithromycin, levofloxacin, or moxifloxacin 1
For Legionella species, the preferred treatment is levofloxacin 750 mg IV/PO daily or moxifloxacin 400 mg IV/PO daily, with an alternative option of azithromycin 1000 mg IV day 1, then 500 mg IV/PO daily or clarithromycin 1, 3

Tetracyclines, such as doxycycline, have a better GI tolerance than macrolides, but may cause photosensitivity, which may limit use in some geographic areas 4
Fluoroquinolones, such as levofloxacin and moxifloxacin, should be reserved for patients intolerant to first-line agents or with treatment failure, and are not recommended as first-line agents to prevent development of resistance 5, 6

For patients with no history of GI intolerance, start with doxycycline 100 mg PO/IV twice daily 1, 2
For patients with a history of tetracycline intolerance, use azithromycin with appropriate antiemetic support if needed 1
For patients with a history of both tetracycline and macrolide intolerance, consider a respiratory fluoroquinolone, such as levofloxacin or moxifloxacin 1, 2

The minimum duration of treatment is 5 days for most cases of atypical pneumonia, with a patient being afebrile for 48-72 hours and having no more than one CAP-associated sign of clinical instability before discontinuation 2
For Mycoplasma pneumoniae, the treatment duration is 7-14 days 1
For Chlamydophila pneumoniae, the treatment duration is 7-10 days 1
For Legionella species, the treatment duration is 7-10 days 1

Inadequate duration of therapy can lead to treatment failure, and ensuring full course completion is essential, even if symptoms improve rapidly 2
Overuse of fluoroquinolones can lead to development of resistance, and they should be reserved for patients who cannot tolerate first-line agents or have treatment failure 5, 6
Failure to switch from IV to oral therapy can lead to prolonged hospitalization, and transitioning to oral therapy when patients are hemodynamically stable and able to tolerate oral intake is recommended 2
Inadequate monitoring for treatment response can lead to delayed recognition of treatment failure, and conducting a careful review of clinical history and examination, and considering additional investigations, is essential for patients who fail to improve as expected 7